Since GAS5 concentrations were controlled by degradation and not by modulation at a transcriptional level, its potential as a biomarker was associated with diabetes mellitus; evolving research using RT-PCR assessed the plasmatic levels of lncRNA GAS5 in patients with plaque psoriasis and revealed significant differences in the relative expression of GAS5 in psoriasis patients versus controls [40]. The gene discussed is GAS5; the disease is diabetes mellitus.